Moderna US trials vaccine against cov-19 is effective, expected to be injected early next year
Foreign media reported that Moderna, a US biotechnology company, announced yesterday (18 May) that preliminary clinical trials for the vaccination of the cov-19 virus To all 45 participants, the results were satisfactory.
Moderna said the vaccine stimulated antibody production in all 45 participants, healthy volunteers aged between 18-55 years.
Moderna revealed that the participants were divided into 3 groups, each receiving 25, 100, and 250 microgram of Coov-19 vaccine.
The result of the experiment indicates that The levels of antibodies in the subjects were similar or greater than those of patients with cowvid-19. Which has already recovered from the said ailment
Moderna said the company will continue the phase 2 trial, which will be a vaccine trial with 600 volunteers after receiving approval from the US Food and Drug Administration (FDA) last month. And the Phase 3 experiment is expected to begin in July if Phase 2 trials are effective
In addition, Moderna stated that If the experiment confirms that the company's vaccines are effective and safe The company is ready to sell the vaccine for use by the beginning of 2021 and expects the company to be able to produce millions of doses by the end of this year. And may produce up to a billion doses next year
News by: slotxo
